Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients

Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients Treated With Biologic Disease Modifying Antirheumatic Drug (DMARD) Therapies

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01137851

Enrollment

3940

Registered

2010-06-07

Start date

2009-11-30

Completion date

2010-09-30

Last updated

2010-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The purpose of this study is to assess the impact of patient cost sharing on treatment discontinuation of biologic agents in patients with Rheumatoid Arthritis (RA)

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Patients diagnosed with Rheumatoid Arthritis (RA) who newly initiated a biologic DMARD (bDMARD) during a study timeframe of 1/01/06 to 3/31/09. Inclusion Criteria: * 18 to 64 years of age at index date * Diagnosis of RA during the study period (ICD-9CM 714.xx) * Evidence of at least one biologic DMARD of interest during the study timeframe * Continuous enrollment during the study timeframe * Both medical and pharmacy benefits * No evidence of a claim for a bDMARD in the 6-month pre-period

Exclusion criteria

* Patients are excluded if they have a diagnosis of psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis at any time during the study timeframe; have a claim for Rituxan, IV etanercept, or IV adalimumab; or have Medicare or Medicaid during the study timeframe

Design outcomes

Primary

Measure	Time frame
Effect of patient cost share on discontinuation	Assessed from first prescription date and followed for 1-year

Secondary

Measure	Time frame
RA-related healthcare utilization and costs	Pre-index: 6-month period prior to the index drug date
All-cause healthcare utilization and costs	Pre-index: 6-month period prior to the index drug date

Outcome results